Vivos Inc. Provides 2021 Recap and Outlines 2022 Objectives
January 24, 2022 09:30 ET
|
Vivos Inc.
Richland WA, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), provides 2021 recap and outlines future objectives. Vivos’ CEO, Dr. Mike Korenko stated, “as we begin 2022, we wanted to...
Vivos Inc. Expands IsoPet® Trademark Protection
May 27, 2021 09:30 ET
|
Vivos Inc.
Richland, WA, May 27, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL). Vivos Inc. previously filed to extend its IsoPet® trademark protection internationally. We are pleased to report that the...
Vivos Inc Enhances Radiogel™ Manufacturing Process
May 24, 2021 09:30 ET
|
Vivos Inc.
Richland WA, May 24, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), During the past few months Vivos has made significant enhancements to the manufacturing process for Radiogel™. These...
Vivos Inc. Provides 2020 Recap and Outlines 2021 Objectives
January 28, 2021 09:30 ET
|
Vivos Inc.
Richland WA, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), provides 2020 recap and outlines future objectives. Vivos’ CEO, Dr. Mike Korenko stated, “as we begin 2021, I think it is...
Vivos Inc Receives Feedback from FDA on Breakthrough Designation Request
January 19, 2021 09:30 ET
|
Vivos Inc.
Richland WA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Although we were unable to secure a Breakthrough Device Designation from the FDA, this was a well-designed process that...
Vivos Inc Completes Surrogate Lymph Node Testing Using Mouse Spleen Injections Demonstrating Uniform Perfusion and Stability
December 09, 2020 09:30 ET
|
Vivos Inc.
Richland WA, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce today that it worked with Mayo Clinic doctors to design and then conduct tests on the...
Vivos Inc to Present at The 13th Annual LD Micro Main Event Conference December 15, 2020 11:00 AM Eastern Standard Time
December 07, 2020 09:30 ET
|
Vivos Inc.
Richland WA, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL``), Vivos Inc (RDGL), a company that has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of...
Vivos Inc Extends it Intellectual Property Protection
December 01, 2020 09:30 ET
|
Vivos Inc.
Richland WA, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that it received the Patent Cooperation Treaty (PCT) International Search Report on our patent...
Vivos Inc Initiates IsoPet Therapy of Horses – Addressing Unmet Need for the Treatment of Equine Tumors
September 03, 2020 09:30 ET
|
Vivos Inc.
Richland WA, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce today that it is expanding Isopet® into the equine market by making IsoPet® available to...
Vivos Inc Provides Update on Initial Indication for Use for RadioGelTM Therapy
August 26, 2020 09:30 ET
|
Vivos Inc.
Richland WA, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), We are excited to announce that based on the recommendation of our Medical Advisory Board, Vivos Inc has decided on treating...